DAFNA Capital Management LLC 13F holdings, Q4 2025
Holdings as of December 31, 2025 · filings on SEC EDGAR · latest filing →
DAFNA Capital Management LLC disclosed 77 US equity positions worth $430.5m in its Q4 2025 13F filing. The largest position was RVMD at 11.2% of the reported book, followed by XBI and STXS. Against the Q3 2025 filing, it opened 4 new positions, added to 12 and reduced 22 among the top 50 holdings.
What did DAFNA Capital Management LLC own in Q4 2025? Top 50 positions
| # | Stock | Sector | Weight | Value | Shares | Δ shares | vs Q3 2025 |
|---|---|---|---|---|---|---|---|
| 1 | RVMD REVOLUTION MEDICINES INC | Healthcare | 11.2% | $48.1m | 604,514 | -8% | reduced |
| 2 | XBI SPDR S&P BIOTECH ETF | 9.5% | $41.0m | 336,505 | -16% | reduced | |
| 3 | STXS STEREOTAXIS INC | 7.3% | $31.5m | 13,680,554 | 0% | held | |
| 4 | ATRC ATRICURE INC | Healthcare | 5.5% | $23.6m | 597,431 | 1% | added |
| 5 | CYTK CYTOKINETICS INC | Healthcare | 5.5% | $23.6m | 370,997 | -6% | reduced |
| 6 | IDYA IDEAYA BIOSCIENCES INC | Healthcare | 4.1% | $17.5m | 506,740 | -6% | reduced |
| 7 | AXGN AXOGEN INC | Healthcare | 3.6% | $15.6m | 476,826 | -36% | reduced |
| 8 | XENE XENON PHARMACEUTICALS INC | Healthcare | 3.0% | $12.9m | 287,939 | 0% | held |
| 9 | IBB ISHARES NASDAQ BIOTECH INDX | 2.7% | $11.5m | 68,095 | -34% | reduced | |
| 10 | BHVN BIOHAVEN LTD | Healthcare | 2.5% | $10.8m | 955,235 | 306% | added |
| 11 | RCUS ARCUS BIOSCIENCES INC | Healthcare | 2.4% | $10.3m | 431,329 | -31% | reduced |
| 12 | NBIX NEUROCRINE BIOSCIENCES INC | Healthcare | 2.3% | $10.0m | 70,615 | 0% | held |
| 13 | DAWNGBX DAY ONE BIOPHARMACEUTICALS I | 2.2% | $9.3m | 999,163 | 0% | held | |
| 14 | TNDM TANDEM DIABETES CARE INC | Healthcare | 1.8% | $7.8m | 355,208 | 0% | held |
| 15 | ASND ASCENDIS PHARMA A/S | Healthcare | 1.4% | $6.0m | 28,177 | -15% | reduced |
| 16 | DXCM DEXCOM INC | Healthcare | 1.4% | $5.9m | 88,279 | 35% | added |
| 17 | SNDX SYNDAX PHARMACEUTICALS INC | Healthcare | 1.4% | $5.8m | 277,855 | -45% | reduced |
| 18 | 4XC1 KALVISTA PHARMACEUTICALS INC | 1.3% | $5.8m | 356,802 | -16% | reduced | |
| 19 | CMPS COMPASS PATHWAYS PLC | Healthcare | 1.3% | $5.6m | 811,046 | 0% | held |
| 20 | INGN INOGEN INC | Healthcare | 1.3% | $5.6m | 827,071 | 37% | added |
| 21 | ASND ASCENDIS PHARMA A/S | 1.3% | $5.5m | 4,000,000 | 0% | held | |
| 22 | DNLI DENALI THERAPEUTICS INC | Healthcare | 1.2% | $5.3m | 318,500 | 89% | added |
| 23 | MBX MBX BIOSCIENCES INC | Healthcare | 1.2% | $5.2m | 165,265 | 94% | added |
| 24 | BCAX BICARA THERAPEUTICS INC | 1.0% | $4.4m | 261,583 | -17% | reduced | |
| 25 | LKFT GALAPAGOS NV | Healthcare | 1.0% | $4.3m | 130,175 | 0% | held |
| 26 | CATBUSD ASTRIA THERAPEUTICS INC | 0.9% | $4.0m | 304,775 | -5% | reduced | |
| 27 | EWTX EDGEWISE THERAPEUTICS INC | 0.9% | $4.0m | 159,736 | -25% | reduced | |
| 28 | IMVT IMMUNOVANT INC | Healthcare | 0.9% | $3.8m | 150,524 | -21% | reduced |
| 29 | PRCT PROCEPT BIOROBOTICS CORP | Healthcare | 0.9% | $3.8m | 120,000 | – | new |
| 30 | HELP CYBIN INC | 0.9% | $3.7m | 455,018 | – | new | |
| 31 | ALKS ALKERMES PLC | Healthcare | 0.8% | $3.6m | 130,248 | -3% | reduced |
| 32 | LRMR LARIMAR THERAPEUTICS INC | Healthcare | 0.8% | $3.6m | 939,164 | -9% | reduced |
| 33 | STOK STOKE THERAPEUTICS INC | Healthcare | 0.8% | $3.5m | 108,875 | -36% | reduced |
| 34 | LXEO LEXEO THERAPEUTICS INC | Healthcare | 0.8% | $3.4m | 340,859 | -5% | reduced |
| 35 | BCRX BIOCRYST PHARMACEUTICALS INC | Healthcare | 0.8% | $3.3m | 418,255 | 92% | added |
| 36 | NKTR NEKTAR THERAPEUTICS | Healthcare | 0.7% | $3.2m | 74,998 | 36% | added |
| 37 | PROQR THERAPEUTICS N V | 0.7% | $3.2m | 1,567,561 | 0% | held | |
| 38 | IPSC CENTURY THERAPEUTICS INC | Healthcare | 0.6% | $2.8m | 2,793,586 | 64% | added |
| 39 | IMTX IMMATICS NV | Healthcare | 0.6% | $2.7m | 261,138 | 11% | added |
| 40 | GPCR STRUCTURE THERAPEUTICS INC | Healthcare | 0.6% | $2.6m | 37,000 | -37% | reduced |
| 41 | MPLT MAPLIGHT THERAPEUTICS INC | 0.6% | $2.5m | 143,764 | – | new | |
| 42 | ALGN ALIGN TECHNOLOGY INC | Healthcare | 0.6% | $2.5m | 16,000 | 45% | added |
| 43 | KURA KURA ONCOLOGY INC | Healthcare | 0.6% | $2.5m | 235,868 | -49% | reduced |
| 44 | AQST AQUESTIVE THERAPEUTICS INC | 0.6% | $2.4m | 375,915 | -27% | reduced | |
| 45 | RAPP RAPPORT THERAPEUTICS INC | 0.5% | $2.3m | 75,000 | 0% | held | |
| 46 | PROF PROFOUND MEDICAL CORP | 0.5% | $2.2m | 285,710 | – | new | |
| 47 | SPRY ARS PHARMACEUTICALS INC | Healthcare | 0.5% | $2.2m | 190,065 | 35% | added |
| 48 | MDWD MEDIWOUND LTD | Healthcare | 0.5% | $2.1m | 113,612 | 0% | held |
| 49 | VKTX VIKING THERAPEUTICS INC | Healthcare | 0.5% | $2.1m | 59,516 | -8% | reduced |
| 50 | PODD INSULET CORP | Healthcare | 0.5% | $2.0m | 6,870 | 0% | held |
Weights are shares of the reported long US equity book (options excluded). Values are as filed, normalised to whole dollars. Share changes compare against the immediately preceding filing only.